within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD11_Catridecacog;

model Catridecacog
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.85e-09,
    adminDuration = 600,
    adminMass = 35 / 1000000,
    adminCount = 1,
    Vd = 0.0423,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0378,
    k12 = 8.88611111111111e-09,
    k21 = 8.88611111111111e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Catridecacog</td></tr><tr><td>ATC code:</td><td>B02BD11</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>35</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>42.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.198</td><td>ml/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Catridecacog is a recombinant human coagulation factor XIII A-subunit used in the treatment and prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. It is approved for medical use in several countries and is administered to prevent or treat bleeding events associated with FXIII deficiency.</p><h4>Pharmacokinetics</h4><p>Reported in adult patients with congenital factor XIII A-subunit deficiency after intravenous administration of 35 IU/kg single dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B02BD11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Catridecacog;
